EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells

Constantin Möller iD, Julia Hambach iD, Alessa Zoe Schaffrath iD, Thomas Eden iD, Sophia Cichutek iD, Anna Josephine Gebhardt iD, Natalie Tode iD, Ronald Maitschke-Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt iD, Marie Eggers iD und 5 weitere

Allergy · 2026-11 · 81 (11) · 3853-3863

DOI: 10.1111/all.70236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 02.02.2026. Verfasst von Constantin Möller und 16 weiteren Autor:innen. Beteiligte Einrichtung: Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germa…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunoglobulin E. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IgE‐associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations.

Methods

In this study, we developed and evaluated a bispecific T‐cell engager (TCE) and a half‐life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE‐producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE‐NKCE constructs were designed to target the CεmX domain of membrane‐bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase‐based cytotoxicity assays using Ramos and U266 B‐cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK‐cell line NK‐92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry.

Results

Both TCE and HLE‐NKCE specifically mediated killing of CεmX‐expressing cells in a dose‐ and effector‐to‐target (E:T) ratio‐dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE‐NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T‐ and NK‐cell activation was observed only in the presence of target cells and TCE.

Conclusion

Our novel anti‐CεmX TCE and HLE‐NKCE effectively target and eliminate mIgE‐expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off‐the‐shelf therapeutics for the treatment of IgE‐associated allergic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunoglobulin EHumansKiller Cells, NaturalT-LymphocytesCell LineHypersensitivityCytotoxicity, ImmunologicDesensitization, ImmunologicLymphocyte Activation

Stichwörter der Autor:innen

EMPD/CεmXIgE‐associated allergic diseasesbispecific NK‐cell engager (NKCE/BiKE/BiNKE)bispecific T‐cell engager (TCE)immunotherapy

Substanzen

Antibodies, BispecificImmunoglobulin E

Autor:innen und Institutionen

  • Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Institute of Immunology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Department of Oncology, Haematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • University Medical Center Hamburg Eppendorf (UKE), Hamburg, Germany.
  • Center for Structural Systems Biology, Hamburg, Germany.
  • European Molecular Biology Laboratory Hamburg, Hamburg, Germany.

ORCID-Profile: Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Susanne Witt, Marie Eggers, Nicola M Tomas, Friedrich Haag, Friedrich Koch-Nolte, Boris Fehse, Kristoffer Riecken

Förderung

  • Deutsche Forschungsgemeinschaft
  • Else Kröner-Fresenius-Stiftung
  • European Research Council

Zitieren

APA

Möller, C., Hambach, J., Schaffrath, A. Z., Eden, T., Cichutek, S., Gebhardt, A. J., Tode, N., Maitschke-Rajasekharan, R., Lewe, P., Qi, S., Witt, S., Eggers, M., Tomas, N. M., Haag, F., Koch-Nolte, F., Fehse, B., & Riecken, K. (2026). Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells. Allergy, 81(11), 3853-3863. https://doi.org/10.1111/all.70236

Vancouver

Möller C, Hambach J, Schaffrath AZ, Eden T, Cichutek S, Gebhardt AJ, et al. Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells. Allergy. 2026;81(11):3853-3863. doi:10.1111/all.70236

BibTeX
@article{Mller2026,
  author = {Möller, Constantin and Hambach, Julia and Schaffrath, Alessa Zoe and Eden, Thomas and Cichutek, Sophia and Gebhardt, Anna Josephine and Tode, Natalie and Maitschke-Rajasekharan, Ronald and Lewe, Philipp and Qi, Sharon and Witt, Susanne and Eggers, Marie and Tomas, Nicola M and Haag, Friedrich and Koch-Nolte, Friedrich and Fehse, Boris and Riecken, Kristoffer},
  title = {Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {11},
  pages = {3853--3863},
  doi = {10.1111/all.70236}
}
Kostenlos starten →